CARANX-MEDICAL
16.4.2024 10:31:35 CEST | Business Wire | Press release
Caranx Medical (‘Caranx’), a French medical device company specializing in the development of autonomous robot to democratize access to Transcatheter Aortic Valve Implantation (TAVI), a lifesaving procedure, today announced the successful world first robotic assisted heart valve (aortic valve) implantation in an animal.
The assisted heart valve implantation in the animal was successfully performed by Dr. Stéphane Lopez, Caranx CMO Dr. Eric Sejor, Caranx CTO Pierre Berthet-Rayne and Caranx team.
“This groundbreaking achievement is the result of hard teamwork. At Caranx Medical, we are dedicated to improving patients' lives through true innovation. This successful transcatheter robotic aortic valve implantation marks the first step toward a new generation of intelligent robots guided by AI, set to transform healthcare as we know it” says Pierre Berthet-Rayne, PhD, co-founder and CTO of Caranx.
“This major medical first lies not only in the technical achievement of Caranx Medical's engineers, but also in the impact that this technology will have on interventional cardiology practice. By simplifying and standardizing a complex procedure, the robot we have developed opens up new possibilities for improving the performance and safety of TAVI procedures” says Dr. Eric Sejor, co-founder and CMO of Caranx.
The TAVI procedure was introduced app. 20 years ago, and still critical challenges and long learning curves are faced by cardiologists during these procedures in a precise and accurate delivery of the heart valve. This is resulting in only 300.000 TAVI procedures being conducted annually in the USA and EU, despite over 1.700.000 eligible patients and the difficulty of the procedure still triggers some drawbacks like frequent need for post procedure pacemakers, due to a lack of precision in the delivery of the implant.
"It is with logic that we prove, and with intuition that we find". “This quote from Henri Poincaré perfectly sums up the work of the Caranx team, who had the intuition, that robotics combined with artificial intelligence and imaging could improve the results of prosthetic heart valve implantation. During this first robotic implantation on a porcine model, the sensations were very similar to those observed during a conventional procedure on our patients. There is no doubt that the use of robotics coupled with artificial intelligence and imaging will improve the safety, precision and reproducibility of the procedure in humans” says Dr. Stéphane Lopez, Institut Arnault Tzanck, Saint Laurent du var, France, who performs more than 400 TAVI procedures per year.
“The team at Caranx, has achieved an important milestone as it successfully deployed a balloon-expandable device in the aortic position, in a pig model. This extremely promising step paves the way to a first-in-human utilization. I am very excited about robotic-assisted TAVI/TAVR, a key to the harmonization of practices as well as the promotion of more predictable and controlled valve deployment. Our patients will undoubtedly benefit from this breakthrough technology in the future” says Dr. Didier Tchétché, Clinique Pasteur, Toulouse, France, who performs more than 1.000 TAVI procedures per year.
According to Frost and Sullivan, the TAVI market is an $8Bn market growing double digits annually.
“With Caranx impressive technology and team, interventional cardiology and physicians can hope for what aircrafts and pilots have been benefiting from for decades: reliable automation, supervised by pilots, imaging and AI for medicine mimicking satellite/GPS systems for flying” says Dr. Philippe Pouletty, co-founder of Caranx and CEO of Truffle Capital.
The Caranx Medical robotic solution, TAVI-PILOT, is a simple, easy-to-use robotic solution, which promises precise, accurate and autonomous valve positioning and delivery. TAVI-PILOT is a revolution for the replacement of the aortic valve, which is restricted because it is reserved for the most experienced cardiologists. Like soft tissue robots have multiplied the number of urologists comfortable to execute a mini-invasive surgical removal of the prostate, TAVI-PILOT will multiply the number of interventional cardiologists to perform safely this life saving procedure.
“This is a major achievement by the Caranx team in the past months. However, at Caranx Medical, we're not just stopping at Aortic valve replacement. Our vision extends to developing our Artificial Intelligence Platform, currently containing more than 5000 of annotated multimodality images of CT, Fluoroscopy, Echo, reports, etc. used to feed our AI algorithms and to revolutionize other endovascular indications, such as mitral and tricuspid valve replacements or even other endoluminal procedures, reshaping the landscape of interventional medicine” says CEO of Caranx, Jorgen Hansen.
About Caranx Medical
Backed by a team of top-tier experts, management team and supported by Truffle Capital, a renowned name in European biotech and MedTech investment, Caranx Medical is a French MedTech company, founded by CMO Dr. Eric Sejor, CTO Pierre Berthet-Rayne, PhD. and Dr. Philippe Pouletty and Truffle Capital, with the ambition to become a global leader in robotic assisted transcatheter heart valve implantation.
Caranx Medical develops the TAVI PILOT, a simple, easy-to-use robotic solution, which promises precise, accurate and autonomous valve positioning and delivery. Caranx Medical’s strategy includes bringing to market TAVI PILOT Soft, an AI intra-operative GPS software which tracks real-time anatomical and instrument landmarks on fluoroscopic images and TAVI PILOT Robotic solution to First in Human in 2025.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416108426/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Redslim expands into Asia-Pacific to support global brands with data and AI infrastructure12.3.2026 07:00:00 CET | Press release
Redslim, a specialist in end-to-end data management solutions and an Astorg portfolio company, today announced its expansion into the Asia-Pacific region and the appointment of Kyriakos Zannikos as Regional Director, APAC. The move marks an important milestone in Redslim’s global growth strategy and brings the company closer to clients operating in one of the world’s fastest-growing and most data-driven consumer markets. As global consumer brands accelerate digital transformation and AI adoption, many organizations still struggle with fragmented data ecosystems spanning multiple agencies, markets and datasets. These challenges are particularly pronounced in Asia-Pacific, where diverse market structures and rapid growth create complex data environments. Redslim helps organizations transform fragmented market information into valuable data assets, empowering clients to make confident decisions and unlock the full value of their data. By building strong data foundations, Redslim supports
Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI12.3.2026 07:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it has initiated a Phase I clinical trial of ME3241 (development code), an anti-PD-1 agonist monoclonal antibody discovered through collaborative research with the Foundation for Biomedical Research and Innovation at Kobe (Headquarters: Kobe, Japan; President: Shuh Narumiya; hereinafter “FBRI”). The Phase I clinical trial is designed as a randomized, placebo-controlled, double-blind study, with the objective of evaluating the safety and tolerability of ME3241 following single and multiple dosing, as well as its pharmacokinetics and pharmacodynamics (ClinicalTrials.gov: NCT07422207). ME3241 was discovered through a collaborative research program led by Program Director Tasuku Honjo, a professor emeritus at Kyoto University. PD-1 is a molecule expressed on activated T cells and other lymphocytes that suppresses immune responses. Through this re
Andersen Consulting styrker sin platform med samarbejdsvirksomheden Ambit Iberia12.3.2026 05:55:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med Ambit Iberia, et konsulentfirma, der specialiserer sig i digitale og regulatoriske løsninger til life science-sektoren. Ambit Iberia, der blev stiftet i 2003, har hovedsæde i Spanien og leverer integrerede løsninger inden for rådgivning, teknologi og rekruttering til medicinal-, bioteknologi- og medtechvirksomheder. Virksomheden hjælper kunder med at opfylde skiftende standarder for kvalitet, compliance og lovgivning gennem ydelser, der spænder over regulatoriske anliggender, dataintegritet, validering af it-systemer og digital transformation. Med mere end 20 års brancheerfaring tilbyder Ambit Iberia også ydelser inden for human capital og executive search, der forbinder organisationer med specialiserede fagfolk og topledertalenter, hvilket øger effektiviteten og fremmer bæredygtig vækst i et stærkt reguleret miljø. "Vores fokus har altid været at levere speciali
EIG’s MidOcean Energy to Acquire Additional Gorgon LNG Interest from JERA; Parties Explore Strategic Alliance12.3.2026 03:14:00 CET | Press release
Transaction increases MidOcean’s equity exposure to premier Australian LNG project Adds incremental uncontracted LNG volumes, enhancing portfolio optimization and marketing flexibility Planning future collaborations, exploring further transactions and opportunities with JERA across other assets globally with the aim of creating a future strategic alliance MidOcean Energy (“MidOcean”), a liquefied natural gas (LNG) company formed and managed by EIG, today announced it has entered into definitive agreements with JERA Co., Inc. (“JERA”) to acquire JERA Gorgon Pty Ltd, which holds JERA’s 0.417% interest in the Gorgon LNG project. MidOcean is an existing participant in the Gorgon LNG project, and this transaction increases MidOcean’s interest in Gorgon to 1.417%. The transaction perimeter also includes JERA’s 0.735% interest in the Ichthys LNG project. Subject to the satisfaction of relevant conditions precedent, the interests in Gorgon and Ichthys will be sold to MidOcean, and then the Ich
DCX Launches Comprehensive ECDU Portfolio – Enterprise-Class Coolant Distribution Units From 600 kW to 2.6 MW11.3.2026 16:34:00 CET | Press release
DCX Liquid Cooling Systems today unveiled its new ECDU (Enterprise Coolant Distribution Unit) platform, a family of three purpose-built CDU models that deliver real cooling capacities from 600 kW to 2.6 MW in industry-standard rack and in-row footprints. The portfolio has been engineered specifically for the accelerating transition to direct-to-chip liquid cooling in high-density enterprise, colocation, cloud, and hyperscale AI environments where thermal stability, uptime, and cost-efficiency are non-negotiable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311214891/en/ DCX ECDU, the new generation of Enterprise Coolant Distribution Units dedicated to HPC and AI deployments. The lineup consists of: Enterprise ECDU 1380/2600 V1 - Delivers 1.38–2.6 MW of actual cooling capacity (based on real-world secondary-loop conditions). Single-pump configuration reaches flow rates up to 3,333 liters per minute (lpm). Mission Critica
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom